Whitfield Advises Moderna in its Strategic Research and Development Collaboration Agreement and Patent Licensing with Immatics
Overview
The Moderna feature concerns a research collaboration and patent-licensing arrangement with Immatics for cancer therapeutics.
Research programs
The described work combines Moderna’s mRNA technology with Immatics’ T-cell-receptor expertise and XPRESIDENT discovery platform. The IMA203 PRAME TCR-T program and an investigational PRAME vaccine are specifically identified.
Financial terms
The account states an upfront payment of $120 million, research support and potential development, regulatory and commercial milestone payments exceeding $1.7 billion. Contingent milestones are not paid consideration.
Advisory team
Shellie Weisfield Freedman and David MacDonald are named as leads; Michael Thorpe and Sarah Lonvick are identified for antitrust work in the source announcement.
